All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
During the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the AML Hub spoke to Mohamad Mohty, Hôpital Saint-Antoine and Sorbonne University, Paris, FR. We asked, When should we use FLAMSA regimens for transplantation conditioning in AML?
FLAMSA-like regimens: When should we use these for transplantation conditioning in AML?
In this video, Mohty summarizes data on allogeneic transplantation presented at the EBMT virtual meeting, regarding the use of FLAMSA (fludarabine, cytarabine, and amsacrine) conditioning regimens for patients with primary refractory or relapsed AML. Mohty believes FLAMSA options are proving to be useful and effective, giving hope to patients waiting for treatment.
Your opinion matters
Subscribe to get the best content related to AML delivered to your inbox